Phage susceptibility testing methods or 'phagograms': where do we stand and where should we go?

被引:1
|
作者
Kolenda, Camille [1 ,2 ]
Jourdan, Julie [1 ]
Roussel-Gaillard, Tiphaine [1 ]
Medina, Mathieu [1 ,2 ]
Laurent, Frederic [1 ,2 ]
机构
[1] Hosp Civils Lyon, Inst Agents Infect, Serv bacteriol, Lyon, France
[2] Univ Claude Bernard Lyon 1, Univ Lyon, CIRI Ctr Int Rech Infectiol, Team StaPath,Inserm,U1111,CNRS,UMR5308,ENS Lyon, Lyon, France
关键词
BACTERIOPHAGE THERAPY; EFFICACY;
D O I
10.1093/jac/dkae325
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Phage therapy is a highly promising approach to address the challenge that is presented by the global burden of antimicrobial resistance. Given the natural specificity of phages, phage susceptibility testing (PST) is a prerequisite for successful personalized therapy, allowing the selection of active phages from large and diverse collections. However, the issue of an easy-to-use and standardized technique remains. In this review, we describe the principles, advantages and drawbacks of two routinely used PST techniques: plaque and growth kinetic assays. These are labour-intensive and time-consuming methods that require automation of one or more steps, including preparation of test panels, incubation, reading and analysis of results. In addition to automation, there is an urgent need to establish a reference method to enable efficient of PST techniques selection of therapeutic phages. We discuss knowledge gaps and parameters that need to be investigated to work towards this goal.
引用
收藏
页码:2742 / 2749
页数:8
相关论文
共 50 条
  • [41] Millet Production and Consumption in India: Where Do We Stand and Where Do We Go?
    Sukumaran Sreekala, Asha Devi
    Anbukkani, P.
    Singh, Alka
    Dayakar Rao, B.
    Jha, Girish K.
    NATIONAL ACADEMY SCIENCE LETTERS-INDIA, 2023, 46 (01): : 65 - 70
  • [42] Millet Production and Consumption in India: Where Do We Stand and Where Do We Go?
    Asha Devi Sukumaran Sreekala
    P. Anbukkani
    Alka Singh
    B. Dayakar Rao
    Girish K. Jha
    National Academy Science Letters, 2023, 46 : 65 - 70
  • [43] High Energy Neutrino Astronomy: Where Do We Stand, Where Do We Go?
    Spiering, Christian
    PHYSICS OF PARTICLES AND NUCLEI, 2018, 49 (04) : 497 - 507
  • [44] Sjogren's syndrome: Where do we stand, and where shall we go?
    Cornec, Divi
    Jamin, Christophe
    Pers, Jacques-Olivier
    JOURNAL OF AUTOIMMUNITY, 2014, 51 : 109 - 114
  • [45] The boundaryless career at 20: where do we stand, and where can we go?
    Arthur, Michael B.
    CAREER DEVELOPMENT INTERNATIONAL, 2014, 19 (06) : 627 - 640
  • [46] TAXES: WHERE DO WE STAND AND WHAT SHOULD WE DO?
    Brice, Benjamin
    ESPRIT, 2024, (11) : 10 - 14
  • [47] Digital human resource development: where are we? Where should we go and how do we go there?
    Thite, Mohan
    HUMAN RESOURCE DEVELOPMENT INTERNATIONAL, 2022, 25 (01) : 87 - 103
  • [48] Phage therapy 2.0: where do we stand?
    Breederveld, Roelf S.
    LANCET INFECTIOUS DISEASES, 2019, 19 (01): : 2 - 3
  • [49] The metrics of technology evaluation: where we stand and where we should go from here
    Geisler, E
    INTERNATIONAL JOURNAL OF TECHNOLOGY MANAGEMENT, 2002, 24 (04) : 341 - 374
  • [50] Introduction Chronic Lymphocytic Leukemia. Where Do We Stand, Where Do We Go
    Foa, Robin
    Montserrat, Emili
    CANCER JOURNAL, 2021, 27 (04): : 257 - 258